|
業務類別
|
Biotechnology |
|
業務概覽
|
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment. |
| 公司地址
| 1600 Sierra Point Parkway, Brisbane, CA, USA, 94005 |
| 電話號碼
| +1 415 660-5320 |
| 傳真號碼
| +1 415 525-4200 |
| 公司網頁
| https://www.nurixtx.com |
| 員工數量
| 317 |
| Dr. Arthur T. Sands, M.D.,PhD |
Director, President and Chief Executive Officer |
美元 613.10K |
28/01/2026 |
| Mr. Hans van Houte |
Chief Financial Officer and Principal Accounting Officer |
美元 498.68K |
28/01/2026 |
| Dr. Gwenn Hansen, PhD |
Chief Scientific Officer |
美元 510.53K |
28/03/2025 |
| Dr. Christine Ring, J.D.,PhD |
Chief Legal Officer, Chief Compliance Officer and Secretary |
美元 498.68K |
28/03/2025 |
|
|
| Ms. Julia P. Gregory |
Chairman of the Board |
28/01/2026 |
| Ms. Judith A. Reinsdorf, J.D. |
Independent Director |
28/01/2026 |
| Dr. Arthur T. Sands, M.D.,PhD |
Director, President and Chief Executive Officer |
28/01/2026 |
| Dr. Roy D. Baynes, M.D.,PhD |
Director |
28/01/2026 |
| Dr. David L. Lacey, M.D. |
Independent Director |
28/01/2026 |
| Mr. Paul M. Silva |
Independent Director |
28/01/2026 |
| Dr. Roger D. Dansey, M.D. |
Director |
28/01/2026 |
| Mr. Edward C. Saltzman |
Independent Director |
28/01/2026 |
| Mr. Anil Kapur |
Independent Director |
28/01/2026 |
|
|
|
|
